Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma

Zhao YunSheng; Zhang LiNa; Huo LiJing; Pei Liu; Li QiuPing; Li HongChen; Jin Liang

doi:10.3969/j.issn.1001-5256.2018.08.023

Issue 8

Aug. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(8): 1707-1711

PDF( 1717 KB)

Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2018.08.023

Department of Clinical Laboratory, Qinhuangdao First Hospital

Research funding:

Received Date: 2018-02-22
Published Date: 2018-08-20

Abstract

Abstract

Objective To investigate the clinical value of serum fucosylated Golgi protein 73 ( Fuc-GP73) in the differential diagnosis of small hepatocellular carcinoma ( s HCC) with a low level of alpha-fetoprotein ( AFP) . Methods A total of 110 patients who were treated in Qinhuangdao First Hospital from April to December, 2014 were enrolled, and among these patients, 50 had s HCC with a low level of AFP ( s HCC group) , 20 had chronic hepatitis B ( CHB group) , 20 had liver cirrhosis ( LC group) , and 20 had malignant tumor in the digestive system except liver cancer ( MTDS group) . A total of 40 individuals who underwent physical examination in our hospital were enrolled as normal controls ( NC group) . Lectin affinity chromatography and ELISA were used to measure the serum level of Fuc-GP73. The Kruskal-Wallis H test was used for comparison of continuous data between multiple groups, and the Nemenyi test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between groups. The receiver operating characteristic ( ROC) curve was plotted to analyze the value of Fuc-GP73 in the diagnosis of s HCC. The logistic regression model was used to evaluate the diagnostic efficiency of the combined measurement of Fuc-GP73 and other markers. Results There was a significant difference in the level of Fuc-GP73 between groups ( H = 87. 225, P = 0. 001) , and the s HCC group had a significantly higher level than the other groups ( all P <0. 05) . The detection rate of Fuc-GP73 was 80% ( 40/50) in the s HCC group, 0 ( 0/20) in the CHB group, 20% ( 4/20) in the LC group, 5% ( 1/20) in the MTDS group, and 0 ( 0/40) in the NC group; there was a significant difference between groups ( χ2= 92. 143, P< 0. 01) , and the s HCC group had a significantly higher detection rate than the other groups ( all P < 0. 01) . In the diagnosis of s HCC, Fuc-GP73 had a sensitivity of 80. 0%, a specificity of 95. 0%, an accuracy rate of 90. 0%, and an area under the ROC curve of 0. 892, and the combined measurement of Fuc-GP73 and other markers had a sensitivity of 96. 0%, a specificity of 98. 0%, an accuracy rate of97. 3%, and an area under the ROC curve of 0. 991. Conclusion Fuc-GP73 can be used as a glycosylated tumor marker for s HCC and is better than AFP.
- carcinoma, hepatocellular,
- Golgi protein 73,
- glycosylation,
- early diagnosis

FullText(HTML)

References(25)

References

[1] JEMAL A, BRAY F, CENTER MM, et al.Global cancer statistics[J].CA Cancer J Clin, 2011, 61 (2) :69-90.

[2]CLARK HP, CARSON WF, KAVANAGH PV, et al.Staging and current treatment of hepatocellular carcinoma[J].Radiographics, 2005, 25 (Suppl 1) :s3-s23.

[3]YAMAMOTO K, IMAMURA H, MATSUYAMA Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J].J Gastroenterol, 2010, 45 (12) :1272-1282.

[4]JOHNSON PJ.The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma[J].Clin Liver Dis, 2001, 5 (1) :145-159.

[5]ZHANG Q, SHAN HL, XU W.Value of serum GP73, AFP, and AFP-L3 in diagnosis of liver cancer and recurrence monitoring after radiofrequency ablation[J].J Clin Hepatol, 2015, 31 (2) :232-235. (in Chinese) 张勤, 单洪丽, 续薇.血清高尔基体糖蛋白73、甲胎蛋白及甲胎蛋白异质体3在肝癌诊断及射频消融术后复发监测中的应用价值[J].临床肝胆病杂志, 2015, 31 (2) :232-235.

[6]MIYOSHI E, MORIWAKI K, NAKAGAWA T.Biological function of fucosylation in cancer biology[J].J Biochem, 2008, 143 (6) :725-729.

[7]WU J, ZHU J, YIN H, et al.Analysis of glycan variation on glycoproteins from serum by the reverse lectin-based ELISA assay[J].J Proteome Res, 2014, 13 (4) :2197-2204.

[8]MA C, ZHANG Q, QU J, et al.A precise approach in large scale core-fucosylated glycoprotein identification with low-and highnormalized collision energy[J].J Proteomics, 2015, 114:61-70.

[9]JIANG K, LI W, ZHANG Q, et al.GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness[J].Oncotarget, 2016, 7 (17) :23530-23541.

[10]JIANG K, SHANG S, LI W, et al.Multiple lectin assays for detecting glyco-alteration of serum GP73 in liver diseases[J].Glycoconj J, 2015, 32 (9) :657-664.

[11]ZHANG S, JIANG K, SUN C, et al.Quantitative analysis of sitespecific N-glycans on sera haptoglobinβchain in liver diseases[J].Acta Biochim Biophys Sin (Shanghai) , 2013, 45 (12) :1021-1029.

[12]WEI FX, LIU Z, GENG J, et al.Research advances in association between Golgi protein 73 and liver diseases[J].J Clin Hepatol, 2017, 33 (8) :1595-1598. (in Chinese) 魏丰贤, 刘钊, 耿婕, 等.高尔基体蛋白73与肝脏疾病的关系[J].临床肝胆病杂志, 2017, 33 (8) :1595-1598.

[13]ZHAO Y, WANG M, CUI C, et al.Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma[J].Cancer Biomark, 2015, 15 (5) :677-683.

[14]BLOCK TM, COMUNALE MA, LOWMAN M, et al.Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J].Proc Natl Acad Sci U S A, 2005, 102 (3) :779-784.

[15]DRAKE RR, SCHWEGLER EE, MALIK G, et al.Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers[J].Mol Cell Proteomics, 2006, 5 (10) :1957-1967.

[16]Chinese Anticancer Association.New standard for diagnosis and treatment of common malignant tumors[M].Beijing:Chinese Union Medical University Press, 1999:389. (in Chinese) 中国抗癌协会.新编常见恶性肿瘤诊治规范[M].北京:中国协和医科大学出版社, 1999:389.

[17]Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association.Prevention and treatment of viral hepatitis[J].Chin J Infect Dis, 2001, 19 (1) :56-62. (in Chinese) 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.

[18] WANG JZ, FAN M.Protein technical manual[M].Beijing:Science Press, 1986:235-243. (in Chinese) 汪家政, 范明.蛋白质技术手册[M].北京:科学出版社, 1986:235-243.

[19]ZHAO YS, WANG M, CUI CY, et al.Clinical significance of eight serum indexes in diagnosis of primary hepatic carcinoma[J].Chongqing Med, 2014, 43 (2) :214-216. (in Chinese) 赵运胜, 王猛, 崔辰莹, 等.评价8种血清标志物在原发性肝癌诊断中的临床价值[J].重庆医学, 2014, 43 (2) :214-216.

[20]YANG SP, LI HY.Diagnostic value of AFP and GP73 test in patients with primary hepatic carcinoma[J].Chongqing Med, 2012, 41 (27) :2880-2882. (in Chinese) 杨收平, 李海英.血清AFP和高尔基体蛋白73联合检测对原发性肝癌的诊断价值[J].重庆医学, 2012, 41 (27) :2880-2882.

[21]SAFFROY R, PHAM P, REFFAS M, et al.New perspectives and strategy research biomarkers for hepatocellular carcinoma[J].Clin Chem Lab Med, 2007, 45 (9) :1169-1179.

[22]WAIDELY E, AL-YUOBI AR, BASHAMMAKH AS, et al.Serum protein biomarkers relevant to hepatocellular carcinoma and their detection[J].Analyst, 2016, 141 (1) :36-44.

[23]OZKAN H, ERDAL H, TUTKAK H, et al.Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma[J].Digestion, 2011, 83 (1-2) :83-88.

[24]KUZMANOV U, KOSANAM H, DIAMANDIS EP.The sweet and sour of serological glycoprotein tumor biomarker quantification[J].BMC Med, 2013, 11:31.

[25]MATSUMOTO H, SHINZAKI S, NARISADA M, et al.Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer[J].Clin Chem Lab Med, 2010, 48 (4) :505-512.

Relative Articles

[1]	Yangqing MA, Haina FAN, Xin SUN, Chenghai LIU. Role of Golgi protein 73(GP73) in diagnosis of chronic liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(8): 1999-2004. doi: 10.3969/j.issn.1001-5256.2023.08.035
[2]	Hang ZHANG, Jinchun LIU. Role of serum Golgi protein 73 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(3): 657-662. doi: 10.3969/j.issn.1001-5256.2023.03.028
[3]	Peiling YE, Hongyun JIA, Liang PENG. Mechanism of action of GP73 in the regulation of liver cancer: An analysis based on transcriptome sequencing[J]. Journal of Clinical Hepatology, 2021, 37(8): 1861-1866. doi: 10.3969/j.issn.1001-5256.2021.08.022
[4]	Zhou Yan, Ning Bo. Application of abnormal cell-free DNA methylation in pancreatic juice in the early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(9): 2145-2148. doi: 10.3969/j.issn.1001-5256.2020.09.054
[5]	Li JiaNa, Zheng RuiQi, Li Na, Hu YuLin. The biological characteristics of GP73 and its value in the diagnosis of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1361-1364. doi: 10.3969/j.issn.1001-5256.2019.06.040
[6]	Chen Jie, Yao MingQi, Wei FeiLi, Xu JinFeng, Guo LeLe, Yang HaiXia, Li Ming, Zhang Jing. Association of N-glycosylation mutation of HBV envelope protein with the development and prognosis of acute-on-chronic liver failure in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(7): 1428-1431. doi: 10.3969/j.issn.1001-5256.2018.07.013
[7]	Zhang LiJun, Liu MingJun, Wang Shuai, Wang Lin, Wang RuKun, Hou HuaBin, Sun GuiRong, Zhang NaNa, Liu LinJie. Clinical value of Golgi protein 73 and hyaluronic acid in diagnosis of the progression of hepatitis B virus-related chronic liver diseases[J]. Journal of Clinical Hepatology, 2018, 34(1): 63-67. doi: 10.3969/j.issn.1001-5256.2018.01.013
[8]	Yao MingJie, Wang LeiJie, Guan GuiWen, Xi JingYuan, Liu ShuHong, Wen XiaJie, Zou Jun, Chen XiangMei, Jia JiDong, Zhao JingMin, Lu FengMin. Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(4): 755-759. doi: 10.3969/j.issn.1001-5256.2018.04.012
[9]	Lu FengMin. Serological diagnosis of hepatocellular carcinoma:challenges and opportunities[J]. Journal of Clinical Hepatology, 2017, 33(7): 1262-1265. doi: 10.3969/j.issn.1001-5256.2017.07.011
[10]	Wei FengXian, Liu Zhao, Geng Jie, Su GuoHong, Chen Mo, Wang ManCai, Cao WeiJia, Zhang YouCheng. Research advances in association between Golgi protein 73 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(8): 1595-1598. doi: 10.3969/j.issn.1001-5256.2017.08.040
[11]	Liu Xu, Guo XiaoZhong. Early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2016, 32(5): 864-866. doi: 10.3969/j.issn.1001-5256.2016.05.008
[12]	Wang Ting, Liu Mei, Dong Lei, Duan ZhongPing. Application of tumor-associated antigens and their autoantibodies in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(7): 1418-1421. doi: 10.3969/j.issn.1001-5256.2016.07.047
[13]	Liu XiuHong, Zhao YiMing, Li Ning, Jin BoXun, Yan HuiPing, Zhao YuanShun, Li Ang, Han Zhen, Zhang AiYing. Diagnostic values of plasma Golgi protein-73 and platelet count for different stages of HBV-related liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(9): 1469-1472. doi: 10.3969/j.issn.1001-5256.2015.09.025
[14]	Zhang Qin, Dan HongLi, Xu Wei. Value of serum GP73,AFP,and AFP-L3 in diagnosis of liver cancer and recurrence monitoring after radiofrequency ablation[J]. Journal of Clinical Hepatology, 2015, 31(2): 232-235. doi: 10.3969/j.issn.1001-5256.2015.02.021
[15]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
[16]	Zhu MingYu, Chen Jie, Zhang XinXin. Research advances in serum biomarkers for early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1091-1093. doi: 10.3969/j.issn.1001-5256.2014.10.029
[17]	Gao HaiFeng. Value of combined detection of serum AFP and GP73 in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(7): 660-662. doi: 10.3969/j.issn.1001-5256.2014.07.022
[18]	Zhu Chen, Sun YuanYuan, Jin Yan. Values of serum AFP, GGTⅡ and GP73 in diagnosis of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1064-1066. doi: 10.3969/j.issn.1001-5256.2014.10.022
[19]	Li HaiPing, Gao Bo, Yu ZongTao, Liu JiuBo, Zhang JiCai. Significance of detection of multigene methylation in liver cancer tissue for early diagnosis of liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(8): 624-626. doi: 10.3969/j.issn.1001-5256.2013.08.018
[20]	Li ZhaoShen. Status and prospects of early diagnosis of pancreatic cancer[J]. Journal of Clinical Hepatology, 2010, 26(5): 451-453+458.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1514) PDF downloads(318)

Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2018.08.023

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2018.08.023

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content